An announcement from Silexion Therapeutics ( (SLXN) ) is now available.
On April 23, 2025, Silexion Therapeutics announced a strategic collaboration with Catalent to develop advanced siRNA formulations and conduct clinical manufacturing activities for SIL204, their next-generation siRNA candidate. This partnership aims to optimize SIL204’s delivery formulations for targeting KRAS-driven cancers, building on promising preclinical results and supporting Silexion’s strategy to advance SIL204 toward clinical trials, with potential regulatory submissions planned for 2025 and 2026.
Spark’s Take on SLXN Stock
According to Spark, TipRanks’ AI Analyst, SLXN is a Underperform.
Silexion Therapeutics is currently facing significant financial challenges, with zero revenue and negative equity posing major risks. The technical analysis reflects bearish momentum, and the valuation metrics highlight the speculative nature of the stock. However, recent corporate events, particularly the progress in SIL204, provide some optimism. Overall, the stock’s score is low, reflecting the high risks and uncertain future prospects.
To see Spark’s full report on SLXN stock, click here.
More about Silexion Therapeutics
Silexion Therapeutics is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for treating solid tumors driven by KRAS mutations, a common oncogenic driver in human cancers. The company is advancing its next-generation siRNA candidate, SIL204, which targets a broad range of KRAS mutations, and has shown significant potential in preclinical studies.
YTD Price Performance: -64.67%
Average Trading Volume: 13,622,855
Technical Sentiment Signal: Buy
Current Market Cap: $6.11M
See more data about SLXN stock on TipRanks’ Stock Analysis page.